Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2015 Jun;15(6):e101-4.
doi: 10.1016/j.clml.2015.02.004. Epub 2015 Feb 11.

IPSET-Thrombosis Better Identifies Thrombosis-Free Survival: A Turkish Cohort

Omur Gokmen Sevindik  1 , Sinan Mersin  2 , Abdullah Katgi  3 , Sunay Tunali  3 , Serife Medeni Solmaz  3 , Celal Acar  3 , Inci Alacacioglu  3 , Ozden Piskin  3 , Mehmet Ali Ozcan  3 , Fatih Demirkan  3 , Bulent Undar  3 , Guner Hayri Ozsan  3
Affiliations
Comparative Study

IPSET-Thrombosis Better Identifies Thrombosis-Free Survival: A Turkish Cohort

Omur Gokmen Sevindik et al. Clin Lymphoma Myeloma Leuk. 2015 Jun.

Abstract

Introduction: Essential thrombocythemia (ET) is the most common of the myeloproliferative neoplasms. For better predicting the occurrence of thrombotic events, an International Prognostic Score of Thrombosis for ET (IPSET-Thrombosis) was recently developed. We aimed to investigate the validity of IPSET-Thrombosis in a Turkish patient cohort and to compare the efficacy of IPSET-Thrombosis and conventional risk scoring systems in predicting thrombosis-free survival.

Patients and methods: We retrospectively evaluated the clinical characteristics and risk factors for thrombosis in 112 Turkish patients. Median thrombosis-free survival and Harrell C concordance indexes were calculated for both conventional and IPSET-Thrombosis.

Results: Median age of 112 patients included in the study was 61 (range, 27-90) years at the time of diagnosis. When patients were stratified according to the conventional risk stratification system, 43.8% of patients were in the low-risk group and 56.2% in the high-risk group. A total of 22.4% of low-risk and 42.9% of high-risk patients had at least one thromboembolic event. When patients were stratified according to the IPSET-Thrombosis, 33% were in the low-risk group, 26.8% in the intermediate-risk group, and 40.2% in the high-risk group. Considering IPSET-Thrombosis risk groups, 5.4% of low-risk, 26.7% of intermediate-risk, and 66.2% of high-risk patients had at least one thromboembolic event. Regarding IPSET-Thrombosis risk groups, 10-year thrombosis-free survival was 86.8% for low-risk, 39.4% for intermediate-risk, and 32.9% for high-risk groups (P < .001). Harrell C concordance indexes of conventional and IPSET-Thrombosis were 0.60 and 0.77, respectively.

Conclusion: By validating the reproducibility of IPSET-Thrombosis in Turkish ET patients, we found that IPSET-Thrombosis identifies thrombosis-free survival better than the conventional risk stratification system.

Keywords: Essential thrombocythemia; IPSET-Thrombosis; Thromboembolism; Thrombosis-free survival; Turkey.

PubMed Disclaimer